Large Cap Pharma
•24 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (24)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly is a large, diversified global pharmaceutical company with a core high-revenue portfolio.
|
$816.66B |
$863.11
+2.20%
|
|
ABBV
AbbVie Inc.
AbbVie is a Large Cap Pharma company with a diversified portfolio and growth trajectory.
|
$385.15B |
$218.07
-4.44%
|
|
AZN
AstraZeneca PLC
AZN is a large-cap pharmaceutical company with a diversified, global drug portfolio and a robust R&D pipeline.
|
$255.44B |
$82.39
+0.06%
|
|
NVO
Novo Nordisk A/S
Novo Nordisk is a leading large-cap pharmaceutical company with blockbuster GLP-1 products Wegovy and Ozempic, a core driver of its revenue and growth.
|
$223.06B |
$49.45
-1.19%
|
|
MRK
Merck & Co., Inc.
Merck is a large, diversified pharmaceutical company with established revenues across human health and animal health.
|
$215.90B |
$85.99
-0.34%
|
|
AMGN
Amgen Inc.
Amgen's scale and diversified, long-tenured drug portfolio align with Large Cap Pharma characteristics.
|
$160.47B |
$298.45
+2.21%
|
|
GILD
Gilead Sciences, Inc.
Gilead is a large, globally diversified pharma company; captured by Large Cap Pharma.
|
$149.01B |
$119.77
+1.12%
|
|
PFE
Pfizer Inc.
Pfizer is a Large Cap Pharma company, reflecting its scale and diversified pharma-centric revenues.
|
$140.14B |
$24.66
+1.50%
|
|
VRTX
Vertex Pharmaceuticals Incorporated
Vertex is a large-cap pharma/biotech with a diversified, revenue-generating portfolio anchored by CFTR modulators and expanding pipeline.
|
$109.29B |
$425.63
+1.37%
|
|
BMY
Bristol-Myers Squibb Company
BMY is a large, diversified global pharma; Large Cap Pharma appropriately tags its scale and breadth.
|
$93.77B |
$46.11
+1.07%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron operates as a large-cap pharmaceutical company with a broad pipeline and scale.
|
$69.08B |
$651.52
-0.39%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda is a large-cap pharmaceutical company with a diversified, high-revenue drug portfolio and pipeline.
|
$42.61B |
$13.44
+1.59%
|
|
BNTX
BioNTech SE
BioNTech is a Large Cap Pharma company with a diversified oncology and vaccine pipeline.
|
$24.91B |
$103.92
-0.72%
|
|
BIIB
Biogen Inc.
Biogen is a Large Cap Pharma with broad, diversified portfolio.
|
$22.62B |
$154.27
+3.11%
|
|
VTRS
Viatris Inc.
Viatris is a Large Cap Pharma company, a broad investable category for diversified pharma players.
|
$12.16B |
$10.36
|
|
RDY
Dr. Reddy's Laboratories Limited
RDY operates as a Large Cap Pharma with a diversified global portfolio.
|
$11.09B |
$13.30
-1.12%
|
|
ELAN
Elanco Animal Health Incorporated
Classification as a Large Cap Pharma/biotech company reflects scale and market position.
|
$11.00B |
$22.14
-1.91%
|
|
BAX
Baxter International Inc.
Pharmaceuticals segment aligns with Large Cap Pharma as Baxter pursues new product launches.
|
$9.48B |
$18.46
-3.63%
|
|
GRFS
Grifols, S.A.
Grifols operates as a large, global pharmaceutical company with a core focus on plasma-derived therapies.
|
$6.44B |
$9.35
+2.07%
|
|
IEP
Icahn Enterprises L.P.
Pharma segment includes global drug development and commercialization activities (eg. Qsiva) typical of Large Cap Pharma companies.
|
$4.40B |
$8.04
-0.37%
|
|
INDV
Indivior PLC
Indivior's flagship SUBLOCADE long-acting injectable is the primary revenue driver and growth engine, placing the company in Large Cap Pharma.
|
$4.05B |
$29.35
+0.76%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
With 2025 revenue guidance around $1.03–$1.095 billion, ACADIA operates at a large-cap pharma scale.
|
$3.80B |
$22.70
-0.20%
|
|
BHC
Bausch Health Companies Inc.
Bausch Health operates as a large-cap pharmaceutical company with a diversified drug and device portfolio.
|
$2.60B |
$7.03
+6.28%
|
|
CRMD
CorMedix Inc.
Melinta acquisition adds a diversified antibiotic portfolio expanding revenue mix into infectious disease therapeutics.
|
$754.89M |
$11.11
-4.39%
|
Loading company comparison...
Loading industry trends...
Loading research report...
